KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBT (2016 - 2025)

Historic EBT for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $50000.0.

  • TherapeuticsMD's EBT rose 10881.83% to $50000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10000.0, marking a year-over-year increase of 10024.94%. This contributed to the annual value of -$2.3 million for FY2024, which is 6973.65% up from last year.
  • As of Q3 2025, TherapeuticsMD's EBT stood at $50000.0, which was up 10881.83% from $545000.0 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's EBT peaked at $50.2 million during Q4 2021, and registered a low of -$47.4 million during Q3 2021.
  • Its 5-year average for EBT is -$4.7 million, with a median of -$1.4 million in 2023.
  • In the last 5 years, TherapeuticsMD's EBT skyrocketed by 21915.79% in 2021 and then crashed by 10326.91% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's EBT stood at $50.2 million in 2021, then dropped by 3.38% to $48.5 million in 2022, then tumbled by 103.27% to -$1.6 million in 2023, then soared by 105.24% to $83000.0 in 2024, then plummeted by 39.76% to $50000.0 in 2025.
  • Its EBT was $50000.0 in Q3 2025, compared to $545000.0 in Q2 2025 and -$668000.0 in Q1 2025.